The FDA last week approved Mylan’s generic alternative to AstraZeneca’s Symbicort inhaler — the first on the market. The Mylan generic was approved to treat both asthma and COPD. For the treatment of asthma, Symbicort holds covered or better status for 89% of all insured lives under the pharmacy benefit. Among all covered lives, 53.4% have preferred access to Symbicort without utilization management restrictions.
SOURCE: MMIT Analytics, as of 3/21/22